

# **Epidermolysis Bullosa (EB) Therapeutics Market Size, Trends, Analysis, and Outlook By Drug (EB-101, Oleogel-S10, Others), By Drug (Antibiotics, Analgesics, Others), By Route of Administration (Injectables, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Homecare, Specialty Clinics, Others), by Region, Country, Segment, and Companies, 2024-2030**

<https://marketpublishers.com/r/E917F78A0DF9EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: E917F78A0DF9EN

## **Abstracts**

The global Epidermolysis Bullosa (EB) Therapeutics market size is poised to register 5.88% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Epidermolysis Bullosa (EB) Therapeutics market By Drug (EB-101, Oleogel-S10, Others), By Drug (Antibiotics, Analgesics, Others), By Route of Administration (Injectables, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Homecare, Specialty Clinics, Others).

The future of epidermolysis bullosa (EB) therapeutics is influenced by advancements in regenerative medicine, gene therapy, and targeted drug delivery. Key trends include the development of novel treatments that address the underlying genetic defects and pathological mechanisms associated with EB, such as gene editing technologies, protein replacement therapies, and cell-based therapies aimed at restoring skin integrity and function. Moreover, there is a growing emphasis on the use of innovative wound healing strategies, including growth factors, stem cells, and tissue-engineered skin

substitutes, to promote tissue regeneration, reduce scarring, and alleviate symptoms in patients with EB-related skin fragility and blistering. Additionally, there is increasing exploration of systemic and topical pharmacological agents, such as anti-inflammatory drugs, pain relievers, and infection control measures, to manage complications and improve quality of life for individuals living with EB. These trends reflect a multidisciplinary approach to EB therapeutics, with a focus on developing comprehensive and personalized treatment strategies that address the complex and diverse clinical manifestations of this rare genetic disorder, ultimately aiming to improve long-term outcomes and quality of life for affected individuals..

## Epidermolysis Bullosa (EB) Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Epidermolysis Bullosa (EB) Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Epidermolysis Bullosa (EB) Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Epidermolysis Bullosa (EB) Therapeutics industry.

## Key market trends defining the global Epidermolysis Bullosa (EB) Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Epidermolysis Bullosa (EB) Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Epidermolysis Bullosa (EB) Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Epidermolysis Bullosa (EB)

Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Epidermolysis Bullosa (EB) Therapeutics industry

Leading Epidermolysis Bullosa (EB) Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Epidermolysis Bullosa (EB) Therapeutics companies.

Epidermolysis Bullosa (EB) Therapeutics Market Study- Strategic Analysis Review

The Epidermolysis Bullosa (EB) Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Epidermolysis Bullosa (EB) Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to

2030 in three case scenarios- low case, reference case, and high case scenarios.

## Epidermolysis Bullosa (EB) Therapeutics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

## North America Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Epidermolysis Bullosa (EB) Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Epidermolysis Bullosa (EB) Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Epidermolysis Bullosa (EB) Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

## Europe Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Epidermolysis Bullosa (EB) Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Epidermolysis Bullosa (EB) Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

## Asia Pacific Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook- an attractive

hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Epidermolysis Bullosa (EB) Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Epidermolysis Bullosa (EB) Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Epidermolysis Bullosa (EB) Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Epidermolysis Bullosa (EB) Therapeutics.

Epidermolysis Bullosa (EB) Therapeutics Market Company Profiles

The global Epidermolysis Bullosa (EB) Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Acadia Pharmaceuticals Inc, Biogen Inc, F. Hoffmann-La Roche Ltd, H. Lundbeck A/S, Merck Sharp & Dohme Corp, Mitsubishi Tanabe Pharma Corp, Novartis AG, Orion Corp, Pfizer

Inc, Sanofi, Teva Pharmaceutical Industries Ltd, UCB S.A..

## Recent Epidermolysis Bullosa (EB) Therapeutics Market Developments

The global Epidermolysis Bullosa (EB) Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

## Epidermolysis Bullosa (EB) Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

## Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Acadia Pharmaceuticals Inc

Biogen Inc

F. Hoffmann-La Roche Ltd

H. Lundbeck A/S

Merck Sharp & Dohme Corp

Mitsubishi Tanabe Pharma Corp

Novartis AG



Orion Corp

Pfizer Inc

Sanofi

Teva Pharmaceutical Industries Ltd

UCB S.A.

Formats Available: Excel, PDF, and PPT

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Epidermolysis Bullosa (EB) Therapeutics Market Overview and Key Findings, 2024
- 1.2 Epidermolysis Bullosa (EB) Therapeutics Market Size and Growth Outlook, 2021-2030
- 1.3 Epidermolysis Bullosa (EB) Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Epidermolysis Bullosa (EB) Therapeutics Market Trends and Challenges
  - 1.4.1 Epidermolysis Bullosa (EB) Therapeutics Market Drivers and Trends
  - 1.4.2 Epidermolysis Bullosa (EB) Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Epidermolysis Bullosa (EB) Therapeutics Companies

### **2. EPIDERMOLYSIS BULLOSA (EB) THERAPEUTICS MARKET SIZE OUTLOOK TO 2030**

- 2.1 Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook, USD Million, 2021-2030
- 2.2 Epidermolysis Bullosa (EB) Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### **3. EPIDERMOLYSIS BULLOSA (EB) THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW**

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### **4. EPIDERMOLYSIS BULLOSA (EB) THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK**

#### 4.1 Market Segmentation and Scope

#### 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

##### By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

##### By Display

Color Ultrasound

B/W Ultrasound

##### By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

##### By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

##### By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

#### 4.3 Growth Prospects and Niche Opportunities, 2023- 2030

#### 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

### 5. REGION-WISE MARKET OUTLOOK TO 2030

#### 5.1 Key Findings for Asia Pacific Epidermolysis Bullosa (EB) Therapeutics Market, 2025

#### 5.2 Asia Pacific Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Type, 2021- 2030

#### 5.3 Asia Pacific Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Application, 2021- 2030

#### 5.4 Key Findings for Europe Epidermolysis Bullosa (EB) Therapeutics Market, 2025

5.5 Europe Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Type, 2021- 2030

5.6 Europe Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Epidermolysis Bullosa (EB) Therapeutics Market, 2025

5.8 North America Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Type, 2021- 2030

5.9 North America Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Epidermolysis Bullosa (EB) Therapeutics Market, 2025

5.11 South America Pacific Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Type, 2021- 2030

5.12 South America Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Epidermolysis Bullosa (EB) Therapeutics Market, 2025

5.14 Middle East Africa Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Epidermolysis Bullosa (EB) Therapeutics Market Size Outlook and Revenue Growth Forecasts

6.2 US Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities

- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts

6.42 Africa Epidermolysis Bullosa (EB) Therapeutics Industry Drivers and Opportunities

## **7. EPIDERMOLYSIS BULLOSA (EB) THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS**

7.1 Low Growth Case

7.2 Reference Growth Case

7.3 High Growth Case

## **8. EPIDERMOLYSIS BULLOSA (EB) THERAPEUTICS COMPANY PROFILES**

8.1 Profiles of Leading Epidermolysis Bullosa (EB) Therapeutics Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

Acadia Pharmaceuticals Inc

Biogen Inc

F. Hoffmann-La Roche Ltd

H. Lundbeck A/S

Merck Sharp & Dohme Corp

Mitsubishi Tanabe Pharma Corp

Novartis AG

Orion Corp

Pfizer Inc

Sanofi

Teva Pharmaceutical Industries Ltd

UCB S.A.

## **9. APPENDIX**

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

## I would like to order

Product name: Epidermolysis Bullosa (EB) Therapeutics Market Size, Trends, Analysis, and Outlook By Drug (EB-101, Oleogel-S10, Others), By Drug (Antibiotics, Analgesics, Others), By Route of Administration (Injectables, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Homecare, Specialty Clinics, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/E917F78A0DF9EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E917F78A0DF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970